SCHEMBL1481968

SCHEMBL1481968

[CH2]c1ccc2cccccc1-2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.46
HSD17B10 Q99714 3/20 0.46
BCL2L1 Q07817 2/20 0.46
MAPK1 P28482 2/20 0.46
HPGD P15428 1/20 0.46
CYP2A6 P11509 1/20 0.46
BACE1 P56817 1/20 0.42
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
PTGS2 P35354 1/20 0.41
DPP4 P27487 1/20 0.41
HDAC4 P56524 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
TDP1 Q9NUW8 2/20 0.38
BCAT2 O15382 1/20 0.38
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL95436 0.92 ALDH1A1 (0.48) ALDH1A1HSD17B10BCL2L1MAPK1HPGD
SCHEMBL27641143 0.89 ALDH1A1 (0.46) ALDH1A1HSD17B10BCL2L1MAPK1HPGD
SCHEMBL8416898 0.88 ALDH1A1 (0.38) ALDH1A1HSD17B10BCL2L1MAPK1HPGD
SCHEMBL27500515 0.86 ALDH1A1 (0.42) ALDH1A1HSD17B10BCL2L1MAPK1HPGD
SCHEMBL27641049 0.82 ALDH1A1 (0.46) ALDH1A1HSD17B10BCL2L1MAPK1HPGD
SCHEMBL97189 0.82 MEN1 (0.52) ALDH1A1HSD17B10HPGDBACE1MEN1
SCHEMBL2092765 0.77 MEN1 (0.40) ALDH1A1MAPK1HPGDTDP1MEN1
SCHEMBL4444745 0.77 ABL1 (0.56) ALDH1A1HSD17B10BCL2L1HPGDBACE1
SCHEMBL2688189 0.77 CYP1A2 (0.50) ALDH1A1HSD17B10HPGDCYP2A6CASP3
SCHEMBL14697496 0.77 ALDH1A1 (0.50) ALDH1A1MAPK1HPGDCYP2A6TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210393634-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES WHICH CONTAINS PYRROLOPYRIMIDINE COMPOUND AS ACTIVE INGREDIENT KEIO UNIVERSITY (JP) 2021-12-23 US disclosed
EP-3821893-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES WHICH CONTAINS PYRROLOPYRIMIDINE COMPOUND AS ACTIVE INGREDIENT Keio University (JP) 2021-05-19 EP disclosed
WO-2019216409-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES WHICH CONTAINS PYRROLOPYRIMIDINE COMPOUND AS ACTIVE INGREDIENT 学校法人慶應義塾 (JP) 2019-11-14 WO disclosed
US-20160145254-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2016-05-26 US disclosed
CN-102471337-B Triazolopyridine compounds and their use as prolyl hydroxylase inhibitors and erythropoietin production inducers JAPAN TOBACCO INC 2014-12-10 CN disclosed
EP-2455381-B9 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER JAPAN TOBACCO INC (JP) 2014-10-22 EP disclosed
EP-2746282-A1 Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor and erythropoietin production inducer Japan Tobacco Inc. (JP) 2014-06-25 EP disclosed
EP-2455381-B1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER JAPAN TOBACCO INC (JP) 2014-05-28 EP disclosed
EP-2143714-B1 TETRAHYDROISOQUINOLINE COMPOUND KOWA CO (JP) 2013-06-05 EP disclosed
US-20130096155-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2013-04-18 US disclosed
US-20120225896-A1 NOVEL 2-PYRIDONE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME KOWA COMPANY, LTD. (JP) 2012-09-06 US disclosed
EP-2455381-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER Japan Tobacco, Inc. (JP) 2012-05-23 EP disclosed
CN-102471337-A Triazolopyridine compounds and their use as prolyl hydroxylase inhibitors and erythropoietin production inducers JAPAN TOBACCO INC 2012-05-23 CN disclosed
US-7956182-B2 Process for preparing optically active alcohols KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) 2011-06-07 US disclosed
US-20110077267-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2011-03-31 US disclosed
US-20100120844-A1 TETRAHYDROISOQUINOLINE COMPOUND KOWA COMPANY, LTD. (JP) 2010-05-13 US disclosed
EP-2143714-A1 TETRAHYDROISOQUINOLINE COMPOUND Kowa Company, Ltd. (JP) 2010-01-13 EP disclosed
CN-101384532-A Method for producing optically active alcohol KOTOBUKI PHARMACEUTICAL CO LTD (JP) 2009-03-11 CN disclosed
US-20090062527-A1 Process for Preparing Optically Active Alcohols KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) 2009-03-05 US disclosed
EP-1988071-A1 METHOD OF PRODUCING OPTICALLY ACTIVE ALCOHOL Kotobuki Pharmaceutical Co., Ltd. (JP) 2008-11-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096155-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT EGLN3, EPOR, EGLN2 ALDH1A1 309/4885HSD17B10 1595/4885BCL2L1 2353/4885
US-20120225896-A1 NOVEL 2-PYRIDONE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME PPARG, PPARD, PPARA ALDH1A1 563/4885HSD17B10 231/4885BCL2L1 3440/4885
US-20090062527-A1 Process for Preparing Optically Active Alcohols ADH1C, ADH1A, ADH5 ALDH1A1 28/4885HSD17B10 394/4885BCL2L1 4213/4885
US-20110077267-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT EGLN3, EPOR, EGLN2 ALDH1A1 309/4885HSD17B10 1595/4885BCL2L1 2353/4885
US-20210393634-A1 PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES WHICH CONTAINS PYRROLOPYRIMIDINE COMPOUND AS ACTIVE INGREDIENT TPMT, IL1B, TSLP ALDH1A1 248/4885HSD17B10 1558/4885BCL2L1 3845/4885
US-20160145254-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT EGLN3, EPOR, EGLN2 ALDH1A1 309/4885HSD17B10 1595/4885BCL2L1 2353/4885
US-20100120844-A1 TETRAHYDROISOQUINOLINE COMPOUND CCR3, CCR5, CCR1 ALDH1A1 2938/4885HSD17B10 1525/4885BCL2L1 3157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.